Carboxylesterase 1 Genetic Variation and Methylphenidate in ADHD
Recruiting
Phase 4
Interventional Study
ADHD
Attention Deficit Hyperactivity Disorder
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 6 – 17
- Sex
- Any
- Trial phase
- Phase 4
- Study type
- Interventional
- Purpose
- Basic Science
- Participants needed
- 500 (estimated)
- Sponsor
- Icahn School of Medicine at Mount Sinai · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The study team will determine the association between d,l-methylphenidate (MPH) therapeutic outcomes in ADHD patients and genetic variants of CES1 and reveal key associations between CES1 genotypes and the PK and PD of MPH.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
\- Youth ages 6-17 years with ADHD as a primary diagnosis
Exclusion Criteria:
* Participants that do not have ADHD as a primary diagnosis
* Participants that do not want, require, or are not healthy enough for a single dose trial of MPH for ADHD per the clinical judgment of th…